Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-35

This is not an unusual reaction on the part of the market. It equates to a company giving a forecast of its profits and then falls short when actuals are announced and the market reacts negatively.

Manipulators and shorters thrive on this sort of information and slam the prices down. I am a bit disappointed in Management having to delay the final BLA by a month and have to chastise Management for being overzealous in its timeline. I am sure that Management was aware of this cockup and tried to cover up by some very positive news on the MSB's filing of clinical efficacy and safety data.

There is a lot of optimism on the approval of Remestencel-L which will eventuate in the coming months and I hold the view that this will materialise.

In the meantime we have to wear the bumpy ride.